Clista Dean
Family · Canal Winchester, OHNPI 1467811695
Payments from drug & device makers
Across 109 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396
- Novo Nordisk$200
- Lilly USA, LLC$197
- Bayer$194
- Dexcom, Inc.$121
- AstraZeneca$110
- plus $565 from 15 others
What the payments were for
- Food & beverage$1,783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $396 |
| Novo Nordisk | 12 | $200 |
| Lilly USA, LLC | 13 | $197 |
| Bayer | 10 | $194 |
| Dexcom, Inc. | 6 | $121 |
| AstraZeneca | 7 | $110 |
| Abbott | 5 | $91 |
| Exact Sciences | 3 | $66 |
| Merck | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Pfizer | 3 | $47 |
| Astellas Pharma US Inc | 2 | $42 |
| Dynavax Technologies Corporation | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Amgen | 2 | $28 |
| Krystal Biotech Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Scynexis, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
How this compares
$1,783 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $61,926 |
| TrulicityDulaglutide | 43 | $51,782 |
| MounjaroTirzepatide | 31 | $35,781 |
| JanuviaSitagliptin Phosphate | 34 | $32,132 |
| RybelsusSemaglutide | 12 | $30,130 |
| OzempicSemaglutide | 20 | $29,160 |
| FarxigaDapagliflozin Propanediol | 12 | $10,395 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,550 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $4,878 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,318 |
| Atorvastatin Calcium | 222 | $2,335 |
| Omeprazole | 154 | $2,077 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $1,966 |
| PrevaliteCholestyramine | 12 | $1,672 |
| Levothyroxine Sodium | 147 | $1,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $197 | $87,56374 claims |
| PfizerEliquis | $47 | $61,92667 claims |
| Novo NordiskRybelsus, Ozempic | $200 | $59,29032 claims |
| MerckJanuvia | $64 | $32,13234 claims |
| AstraZenecaFarxiga, Symbicort | $110 | $17,94433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.
Other family in Canal Winchester
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.